Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

301

HTML

2685

Figures (1-2)

238

Tables (1-1)

217

Sum=3441

Publishing Process of This Article

Item

Count

Browse

1023

Download

674

Sum=1697

Jun 27, 2013 (publication date) through Nov 28, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Hepatol. Jun 27, 2013; 5(6): 332-335
Published online Jun 27, 2013. doi: 10.4254/wjh.v5.i6.332

Table 1 Patient characteristics

Characteristics
Age, yr	69
Sex	Male
Race	African-American
HCV treatment history	Partial responder
IL-28B polymorphism	CT
Treatment duration before liver transplant, wk	24
Antiviral treatment toxicity	Hematologic (anemia, neutropenia, thrombocytopenia)

HCV: Hepatitis C virus; CT: Computed tomography; IL-28B: Interleukin-28B.

Citation: Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol 2013; 5(6): 332-335
URL: https://www.wjgnet.com/1948-5182/full/v5/i6/332.htm
DOI: https://dx.doi.org/10.4254/wjh.v5.i6.332